HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer

High mobility group box 1 (HMGB1) is an ubiquitous protein that plays different roles in the nucleus, cytoplasm, and extracellular space. It is an important DAMP molecule that allows communication between damaged or tumor cells and the immune system. Tumor cells exploit HMGB1's ability to activate intracellular pathways that lead to cell growth and migration. Papillary thyroid cancer is a well-differentiated tumor and is often used to study relationships between cells and the inflammatory microenvironment as the latter is characterized by high levels of inflammatory cells and cytokines. Anaplastic thyroid cancer is one of the most lethal human cancers in which many microRNAs and tumor suppressor genes are deregulated. Upregulation of microRNAs 221 and 222 has been shown to induce the malignant phenotype in many human cancers via inhibition of PTEN expression. In this study we suggest that extracellular HMGB1 interaction with RAGE enhances expression of oncogenic cluster miR221/222 that in turn inhibits tumor suppressor gene PTEN in two cell lines derived from human thyroid anaplastic and papillary cancers. The newly identified pathway HMGB1/RAGE/miR221/222 may represent an effective way of tumor escape from immune surveillance that could be used to develop new therapeutic strategies against anaplastic tumors.

[1]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[2]  A. Fusco,et al.  High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs , 2014, BMC Cancer.

[3]  T. Billiar,et al.  High‐mobility group box‐1 in sterile inflammation , 2014, Journal of internal medicine.

[4]  S. Batra,et al.  Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor. , 2014, Biochimica et biophysica acta.

[5]  W. Chng,et al.  MicroRNA: Important Player in the Pathobiology of Multiple Myeloma , 2014, BioMed research international.

[6]  M. A. Marcello,et al.  The role of the inflammatory microenvironment in thyroid carcinogenesis. , 2014, Endocrine-related cancer.

[7]  C. Croce,et al.  Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7 , 2014, Proceedings of the National Academy of Sciences.

[8]  Jun Liu,et al.  NF-kappaB-dependent MicroRNA-425 upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1β induction , 2014, Molecular Cancer.

[9]  Wei Jiang,et al.  High Mobility Group Box-1 Promotes the Proliferation and Migration of Hepatic Stellate Cells via TLR4-Dependent Signal Pathways of PI3K/Akt and JNK , 2013, PloS one.

[10]  F. Consorti,et al.  HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. , 2012, Oncology reports.

[11]  Roberta Galli,et al.  MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response , 2012, Proceedings of the National Academy of Sciences.

[12]  F. Yu,et al.  Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[13]  C. Montagna,et al.  Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors , 2011, Oncotarget.

[14]  A. Hui,et al.  Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies , 2011, BMC Cancer.

[15]  N. Guevara,et al.  Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland? , 2011, Endocrine-related cancer.

[16]  Wei Zhang,et al.  Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release , 2011, Cancer Immunology, Immunotherapy.

[17]  F. Consorti,et al.  Cross-talk between NO and HMGB1 in lymphocytic thyroiditis and papillary thyroid cancer. , 2010, Oncology reports.

[18]  P. Pu,et al.  MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN , 2010, BMC Cancer.

[19]  S. Drexler,et al.  The role of toll-like receptors in chronic inflammation. , 2010, The international journal of biochemistry & cell biology.

[20]  C. Croce,et al.  Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. , 2010, Endocrine-related cancer.

[21]  B. Prabhakar,et al.  Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[22]  M. Willingham,et al.  PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer , 2009, Oncogene.

[23]  J. Copland,et al.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. , 2008, Endocrine-related cancer.

[24]  P. Hou,et al.  Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. , 2008, The Journal of clinical endocrinology and metabolism.

[25]  J. Delcros,et al.  Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. , 2008, Endocrine-related cancer.

[26]  Simon C Watkins,et al.  High Mobility Group Box I (HMGB1) Release From Tumor Cells After Treatment: Implications for Development of Targeted Chemoimmunotherapy , 2007, Journal of immunotherapy.

[27]  Haichao Wang,et al.  A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. , 2007, Blood.

[28]  K. Tracey,et al.  HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2 , 2006, Shock.

[29]  F. Consorti,et al.  HMGB 1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells , 2012 .

[30]  C. Croce,et al.  miR221/222 in cancer: their role in tumor progression and response to therapy. , 2012, Current molecular medicine.

[31]  W. Marsden.  I and J , 2012 .

[32]  C. Downes,et al.  Indirect mechanisms of carcinogenesis via downregulation of PTEN function. , 2010, Advances in enzyme regulation.

[33]  Michiteru Yoshida,et al.  HMGB proteins and transcriptional regulation. , 2010, Biochimica et biophysica acta.

[34]  F. Consorti,et al.  Cross-talk between NO and HMGB 1 in lymphocytic thyroiditis and papillary thyroid cancer , 2022 .